How effective is vepotuzumab (POLIVY)?

Vepotolizumab (POLIVY) is a drug targeting CD79b-positive diffuse large B-cell lymphoma (DLBCL). Its use as part of a targeted therapy in combination with other drugs could provide a new treatment option, especially in adult patients with DLBCL who have failed at least two previous treatments.

Clinical trial studies on vepotuzumab have shown that it shows certain efficacy in the treatment of CD79b-positive DLBCL patients. In a pivotal clinical trial, vepotuzumab, in combination with chemotherapy, showed significant prolongation of time to death and increased response rates in patients with DLBCL whose disease had progressed despite multiple lines of therapy. Vepotolizumab itself has certain toxicity and side effects, including anemia, neutropenia, thrombocytopenia, peripheral neuropathy, fatigue, diarrhea, increased body temperature, decreased appetite, and pneumonia.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.